A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Exclusion Criteria

• •Pregnant or breast feeding
• •Any condition which places the subject at risk
• •Systemic fungal infection
• •History of TB infection within 3 years
• •History of recurrent bacterial infection
• •Mycobacterium TB as indicated by a positive PPD skin test
• •History of incompletely treated Mycobacterium tuberculosis
• •Clinically significant chest x-ray abnormality at screening.
• •Clinically significant ECG abnormality at screening
• •History of HIV infection
• •History of congenital or acquired immunodeficiency
• •Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening
• •Antibodies to Hepatitis C at screening
• •History of malignancy (except for treated basal-cell skin carcinomas \> 3 years prior to screening)
• •Any active major organ involvement of Behçet Disease
• •Use of concomitant immune modulating therapy or topical corticosteroids.
• •Use of ocular corticosteroids
• •Use of any investigational medication within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer)